Literature DB >> 2081718

The in-vitro antibiotic susceptibility of Chlamydia pneumoniae.

L E Fenelon1, G Mumtaz, G L Ridgway.   

Abstract

A cell culture technique was used to test the in-vitro susceptibility of the type strain of Chlamydia pneumoniae to 23 antibiotics including macrolides, tetracyclines and quinolones. The activity of the antibiotics tested was similar to previous findings with C. trachomatis. Clarythromycin had the lowest MIC overall (0.007 mg/l). Other macrolides were found to have similar MICs to erythromycin (0.06 mg/l). Both the macrolides and the tetracyclines were more active than the quinolones. It is proposed that the tetracyclines and erythromycin should be the drugs of choice for treating infections with C. pneumoniae; however several other antibiotics need to be evaluated.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2081718     DOI: 10.1093/jac/26.6.763

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.

Authors:  Laura Lawrence; Paul Danese; Joe DeVito; Francois Franceschi; Joyce Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2008-03-03       Impact factor: 5.191

Review 2.  Spectrum of activity of azithromycin.

Authors:  J D Williams
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

Review 3.  Chlamydia pneumoniae: defining the clinical spectrum of infection requires precise laboratory diagnosis.

Authors:  S J Bourke; N F Lightfoot
Journal:  Thorax       Date:  1995-09       Impact factor: 9.139

4.  Chlamydial respiratory infections.

Authors:  S J Bourke
Journal:  BMJ       Date:  1993-05-08

Review 5.  Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae.

Authors:  M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

6.  In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against chlamydia.

Authors:  Y Niki; M Kimura; N Miyashita; R Soejima
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

Review 7.  Chlamydia pneumoniae (TWAR).

Authors:  C C Kuo; L A Jackson; L A Campbell; J T Grayston
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

8.  In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents.

Authors:  M Kimura; T Kishimoto; Y Niki; R Soejima
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

9.  In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.